ClinicalTrials.gg
RecruitingNCT07749170Updated Nov 12, 2026

FORWARD: Functional Outcomes in Real-World Treatment And Revascularization of Non-dominant and Distal M2 Occlusions

An observational study in Acute Ischemic Stroke and Acute Ischemic Stroke (AIS) Related to a Distal Occlusion, sponsored by Penumbra Inc.. Recruiting at 10 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by Penumbra Inc. · Observational

How we know

From the registry’s dates

  • Started Jun 2026; still recruiting 4 months later.
Updated Nov 12, 20269 sites addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
250
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 14 studies in Ischemic Stroke by Penumbra Inc. — 2 open to participants now, 2 under way, none of them phase 3. Ischemic Stroke · Penumbra Inc..

Started
2026
the only one that year
Observational
9 of 14
2 open now
Registered
14th of 14
by date

Among the 14 studies in Ischemic Stroke by Penumbra Inc., this one is the only one that started in 2026, is one of 9 observational ones, and was the 14th registered.

Ischemic Stroke

2,629 studies on the registry are indexed under Ischemic Stroke; 983 are open to participants now.

Browse Ischemic Stroke studies →

Open to participants now

2 of the 14 studies in Ischemic Stroke by Penumbra Inc. are open now, in 6 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 668 Ischemic Stroke studies recruiting now, 403 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 27 take children under 18; 41 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Ischemic Stroke by Penumbra Inc., or all of them as a file.
02

Study summary

The objective of this study is to collect safety and effectiveness data on the Penumbra System reperfusion catheters in participants with isolated primary non-dominant and distal M2 occlusions who undergo endovascular mechanical thrombectomy (EVT). Additionally, this study aims to observe characteristics and outcomes of participants treated with medical management (MM) alone and those who receive EVT + MM per current medical practice.

Read the detailed description

FORWARD is a prospective, multicenter, observational study that will be conducted internationally.

Participants who satisfy all inclusion criteria and none of the exclusion criteria will be eligible for enrollment. They will receive treatment according to the physicians' clinical judgement per standard of care at their institution.

03

Conditions studied

  • Acute Ischemic Stroke
  • Acute Ischemic Stroke (AIS) Related to a Distal Occlusion

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Participants experiencing acute ischemic stroke (AIS) due to a primary M2 occlusion in the vertical segment or post-bifurcation in the non-dominant or co-dominant branch of the horizontal segment.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participant age ≥ 18
  2. Participant experiencing acute ischemic stroke due to a confirmed primary M2 occlusion in the vertical segment or post-bifurcation in the non-dominant or co-dominant branch of the horizontal segment
  3. NIHSS ≥5 or NIHSS 3-4 with disabling symptoms
  4. Pre-stroke mRS 0-1
  5. For participants undergoing thrombectomy: Planned treatment with Penumbra System reperfusion catheters
  6. obtained per Institutional Review Board/Ethics Committee requirements

Exclusion criteria

Exclusion Criteria:

  1. Any stenosis or occlusion in the ICA origin requiring treatment during the procedure or within the 90-day follow-up period.
  2. Known multiple occlusions
  3. Secondary M2 occlusion
  4. Known or high suspicion of underlying ICAD as the cause of the M2 occlusion
  5. Current hospitalization at time of stroke onset and/or any comorbid disease or condition expected to compromise survival or ability to complete follow-up assessments through 90 days
  6. Currently participating in an (drug, device, etc.) clinical trial that will influence the endovascular procedure or acute treatment. Participants in secondary prevention, observational, natural history and/or epidemiological studies are eligible.
  7. Other medical, behavioral, or psychological conditions that in the opinion of the Investigator could limit the ability to participate in the study, including compliance with follow-up requirements, or that could impact the scientific integrity of the study
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
250 participants (estimated)
Patient registry
No

Groups and cohorts

  • Medical Management

    Other: Medical Management

  • Endovascular Thrombectomy plus Medical Management

    Device: Endovascular Thrombectomy · Other: Medical Management

Interventions

  • DeviceEndovascular Thrombectomy

    Patients will undergo endovascular thrombectomy plus medical management. Patients will be treated with the Penumbra System Reperfusion Catheters. Perioperative and postoperative management will follow established guidelines for the care of stroke patients.

  • OtherMedical Management

    All medical management treatment will follow established guidelines for the care of stroke patients. All medical treatments and supportive care will be administered following each participating hospital's routine practice and in accordance with the Instructions for Use for any medication administered.

06

What researchers measure

Primary outcomes

  1. Change in NIHSS at 24 hours

    The National Institutes of Health Stroke Scale (NIHSS) is a standardized neurological examination tool used to measure the severity of a stroke. The scale ranges from 0 to 42, with higher scores indicating greater impairment.

    Time frame: 24 hours

Secondary outcomes

  1. 90-day Modified Rankin Scale (mRS)

    The modified Rankin Scale (mRS) is used to measure the degree of disability or dependence in daily activities in people who have experienced a stroke. Scores range from no symptoms (0) to death (6), with higher scores indicating greater severity.

    Time frame: 90 Days

  2. Reperfusion measures, quantified as proportion of participants with a final mTICI 2b or higher after all treatment

    Time frame: Treatment/Procedure

  3. 90-day NIHSS

    The National Institutes of Health Stroke Scale (NIHSS) is a standardized neurological examination tool used to measure the severity of a stroke. The scale ranges from 0 to 42, with higher scores indicating greater impairment.

    Time frame: 90 Days

  4. Quality of Life, as measured by Barthel Index

    The Barthel Index is a 0-100 point scale used to measure a person's functional independence in daily activities. The index rates 10 items, including feeding, bathing, grooming, dressing, bowel/bladder control, toilet use, transfers, mobility, and stair use. Higher scores indicate greater independence, while lower scores signify higher dependency on caregivers.

    Time frame: 90 Days

  5. Quality of Life, as measured by Neuro-QoL

    Neuro-QoL is a set of patient-reported outcome measures designed to assess health-related quality of life across physical, mental, and social domains relevant to individuals with neurological conditions. It uses calibrated item banks and short forms to measure constructs such as mobility, cognitive function, emotional/behavioral health, fatigue, and social participation.

    Time frame: 90 Days

  6. Quality of Life, as measured by Canadian Outcome Scale for Minor Stroke (COSMOS)

    COSMOS is a 7-point scale ranging from 0 (no symptoms) to 6 (loss of independence for an instrumental or basic activity of daily living or worse), which accounts for performance limitations and losses of a person's hobbies or passions and of their employment, educational, service, or caregiving pursuits, besides just activities of daily living.

    Time frame: 90 Days

  7. Safety events of interest

    Time frame: Treatment, Procedure (if applicable), 24 Hours, Discharge and/or 7 Days, 90 Days

  8. Treatment method per the physician's clinical judgment

    Time frame: Baseline

07

Study locations

10 of 10 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

3 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2026 (actual). Primary completion is estimated for Sep 2028, 27 months after the start.

Of 42 industry-sponsored observational studies under Ischemic Stroke, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 50. This study's planned 27 months is close to that.

Counting every sponsor, half of 443 studies reached it within 53 months; a quarter within 24 and three quarters within 127.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 8, 2026
First posted
Aug 6, 2026
StartActual
Jun 26, 2026
Primary completionEst.
Sep 2028
CompletionEst.
Sep 2028
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
9 sites added
Show 9 added (9 United States)
  • Swedish Medical Center · Englewood, United States
  • Yale New Haven Hospital · New Haven, United States
  • University of Kentucky · Lexington, United States
  • Semmes Murphey · Memphis, United States
  • Wellspan York Hospital · York, United States
  • Medical University of South Carolina (MUSC) · Charleston, United States
  • North Shore University Hospital · Manhasset, United States
  • Stony Brook Medical Center · Stony Brook, United States
  • New Hanover Regional Medical Center · Wilmington, United States
across 3 updates, Oct 15, 2026 – Nov 12, 2026
Show all 3 updates
  1. Nov 12, 2026
    3 sites added
    Show 3 added (3 United States)
    • North Shore University Hospital · Manhasset, United States
    • Stony Brook Medical Center · Stony Brook, United States
    • New Hanover Regional Medical Center · Wilmington, United States
    + 1 other change: verification date
  2. Oct 29, 2026
    2 sites added
    Show 2 added (2 United States)
    • Wellspan York Hospital · York, United States
    • Medical University of South Carolina (MUSC) · Charleston, United States
  3. Oct 15, 2026
    4 sites added
    Show 4 added (4 United States)
    • Swedish Medical Center · Englewood, United States
    • Yale New Haven Hospital · New Haven, United States
    • University of Kentucky · Lexington, United States
    • Semmes Murphey · Memphis, United States
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07749170
Lead sponsor
Penumbra Inc.
Responsible party
Sponsor
First posted
Aug 6, 2026
Start date
Jun 26, 2026
Primary completion
Sep 2028 (estimated)
Completion
Sep 2028 (estimated)
Last update
Nov 12, 2026

Study contacts

Madeline Turtle
Contact
MTurtle@PENUMBRAINC.COM
260-224-8231
Jennifer Jelf
Contact
jjelf@penumbrainc.com
510-440-5719
Alejandro Spiotta, MD
principal investigator · Medical University of South Carolina
Nitin Goyal, MD
principal investigator · University of Tennessee Health Science Center/Semmes Murphey Clinic

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion